Iran launched a surprise ballistic missile attack on U.S. forces in the Middle East on Tuesday morning, shattering a ceasefire that had held for just four days. The Pentagon described the barrage as a "violent escalation" in a conflict approaching its sixth month. For defense investors, the calculus is brutally simple: the war is consuming weapons and digital infrastructure faster than the industrial base can replace them, and the companies supplying those systems face years of uninterrupted demand.
Among the prime beneficiaries, one name stands out as deeply misunderstood by the market. Leidos Holdings is not a platform builder like Lockheed Martin or Northrop Grumman. What Leidos does — C5ISR command and control, cybersecurity, artificial intelligence for battlefield decision-making, signals intelligence processing — is the digital nervous system of modern warfare. When the Pentagon needs to fuse sensor data from a thousand sources into a single targeting picture, Leidos builds the spine.
The stock, however, trades as if none of that matters. Shares have been battered this year, punished by a market fixated on the Defense Health Agency's electronic health records contract transition. The market has treated it as if the entire company rises and falls on one government IT program. That thesis has never survived close examination of the numbers.
Leidos enters the second half of 2026 with a total backlog of $48.4 billion, of which $9.6 billion is funded and executable — up 31 percent year over year. That growth rate would be impressive for any defense contractor, let alone one trading at a single-digit forward multiple. The portfolio spans classified and unclassified contracts across the Department of Defense, the Intelligence Community, Homeland Security, and allied foreign governments.
The past twelve months produced a string of awards that read like a procurement wish list. The MACRO II contract worth up to $869 million for Army AI decision-making. The GSM-O II program added more than $461 million in cybersecurity task orders for DISA. The NSA's TechSIGINT contract expanded Leidos's signals intelligence role by $335 million. And the Army's IFPC Inc 2 air-defense production program carries a ceiling of roughly $1.2 billion for Leidos's contribution.
The financial picture reinforces the disconnect. Leidos generated approximately $17.33 billion in trailing twelve-month revenue at an 8.2 percent profit margin, with free cash flow of roughly $1.9 billion. First-quarter results showed revenue of $4.4 billion, up 4 percent year over year, and non-GAAP earnings per share of $3.13 — a 5 percent beat. Management raised full-year guidance to $18.0 billion to $18.4 billion, reflecting confidence that defense demand is structural, not cyclical.
And yet the stock trades at roughly nine times forward earnings — a valuation more typical of a mature industrial company facing headwinds than a defense technology contractor with a $48.4 billion backlog. The comparison is jarring: Raytheon Technologies, the missile-maker that reported its own blockbuster quarter last week, trades at roughly 18 times forward earnings. Leidos provides the digital infrastructure that makes those missiles effective, at half the multiple.
Wall Street sees the gap. JPMorgan maintains a $160 target. Truist is at $160. Goldman Sachs, at $152, still sees significant appreciation. The consensus across seventeen analysts stands at roughly $164 — a 40 percent premium. The bull case does not rely on a resolution of the health IT overhang. It relies on the arithmetic of a company generating roughly $1.9 billion in free cash flow against a manageable $6.94 billion in debt, with a customer whose procurement budget is accelerating by the month.
Leidos reports fiscal second-quarter earnings on August 4, just six days from now. The June quarter will be the first real look at normalized wartime demand for defense IT under the accelerated procurement authorities the Pentagon activated in March. Analysts expect revenue of roughly $4.44 billion and earnings per share of $2.91. The company has invested in the next generation of warfare — partnerships with The Modern Data Company for defense AI pipelines, and with Rune Technologies for machine learning military logistics. In July, Leidos demonstrated a tactical cyber detection capability during Valiant Shield 2026. These flow directly into the backlog.
The missile attack this morning is not a reason to buy Leidos. The $48.4 billion backlog that existed before the attack, and the valuation discount the market has refused to close, were already reason enough. What the attack does is serve as a reminder that the defense supercycle is not a forecast. It is the current operating environment. Leidos is the baby thrown out with the bathwater — a defense technology powerhouse hiding in plain sight at a price that assumes the war is ending. The war just proved it is not.
Disclosure: The Signal holds no position in LDOS. Positions may change. This is not financial advice.
